Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | SSTR5 | P35346 | 12/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL736580 | 0.84 | OPRM1 (0.57) | SIGMAR1OPRM1SSTR5ADRA1ANPY5R | |
| SCHEMBL737490 | 0.83 | SIGMAR1 (0.58) | SIGMAR1OPRM1USP2ALDH1A1CYP3A4 | |
| SCHEMBL738895 | 0.83 | SIGMAR1 (0.52) | SIGMAR1OPRM1SSTR5ADRA1ANPY5R | |
| SCHEMBL736062 | 0.80 | HRH3 (0.55) | SIGMAR1OPRM1SSTR5KCNH2ALDH1A1 | |
| SCHEMBL735135 | 0.80 | SSTR5 (0.46) | SIGMAR1SSTR5 | |
| SCHEMBL736597 | 0.79 | HRH3 (0.56) | SIGMAR1OPRM1KCNH2ALDH1A1SMN1; SMN2 | |
| SCHEMBL3041181 | 0.79 | NPY5R (0.74) | SIGMAR1OPRM1SSTR5ADRA1ANPY5R | |
| SCHEMBL736292 | 0.77 | HRH3 (0.50) | SIGMAR1OPRM1SSTR5KCNH2ALDH1A1 | |
| SCHEMBL736184 | 0.75 | HRH3 (0.56) | SIGMAR1OPRM1KCNH2ALDH1A1SMN1; SMN2 | |
| SCHEMBL736984 | 0.74 | SIGMAR1 (0.55) | SIGMAR1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138206-B2 | Piperidine derivative | MSD. K.K. (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20090137576-A1 | Novel Piperidine Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1892241-A1 | NOVEL PIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137576-A1 | Novel Piperidine Derivative | HRH4, HRH3, HRH1 | SIGMAR1 11/4885OPRM1 15/4885SSTR5 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.